CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
GSK573719 +1 moredrug
Likely dose
GSK573719 250 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00515502
NCT00515502Phase 2Completed
CompareCT.gov

A Randomised, Double Blind, Placebo-controlled, Double Dummy, 4-way Cross-over, Dose Ascending Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK573719 (250, 500 and 1000 μg) and Tiotropium Bromide (18 μg) Via DPI in COPD Patients.

GlaxoSmithKline·interventional·Posted Aug 13, 2007·Updated Aug 22, 2017

In Brief

A Phase 2 clinical trial evaluating GSK573719 and Tiotropium for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 24 participants across 3 sites.

Detailed Summary

GSK573719 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for once daily treatment of chronic obstructive pulmonary disease (COPD). The long duration of action of GSK573719 when administered via inhalation in animal models supports the potential for use as a once-daily bronchodilator for COPD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesGermany
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 13, 2007
Enrollment StartJun 21, 2007
Primary CompletionNov 6, 2007
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 18.9 years ago

Interventions

GSK573719drug

250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg

Tiotropiumdrug

strips of five capsules, each containing 18 μg administered via dry powder inhaler